Way to Safety Cellphone Blocking
NCT02416713 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2019-02-28
Summary
Research participants will be recruited to take part in a randomized control trial. Participants' cellphone use will be observed during an initial baseline period. Participants will then be randomly assigned to one of four conditions: education only (control), opt-in blocking, opt-out blocking, and opt-out blocking with parental notification.
Conditions
- Teen Drivers
- Motor Vehicle Accident
Interventions
- DEVICE
-
Cellcontrol DriveID
Technology that blocks incoming and outgoing calls and texts.
- OTHER
-
Education Only
No active intervention, educational materials will be provided
Sponsors & Collaborators
- collaborator OTHER
-
Children's Hospital of Philadelphia
lead OTHER
Principal Investigators
-
Catherine McDonald, PhD, RN · Children's Hospital of Philadelphia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-04-13
- Primary Completion
- 2017-03-24
- Completion
- 2017-03-24
Countries
- United States
Study Locations
More Related Trials
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT03849651 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
NCT02345850 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children
NCT00254722 ·Status: COMPLETED ·Phase: PHASE1
-
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
NCT02277639 ·Status: COMPLETED ·Phase: PHASE2
-
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
NCT05968170 ·Status: WITHDRAWN ·Phase: NA
-
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00005641 ·Status: TERMINATED ·Phase: PHASE2
-
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
NCT01866839 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT
NCT07319000 ·Status: COMPLETED ·Phase: PHASE2
-
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
NCT04088760 ·Status: TERMINATED ·Phase: PHASE2
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
NCT00782145 ·Status: COMPLETED ·Phase: PHASE3
-
Novel Mobile Device Application to Improve Adherence
NCT02904278 ·Status: COMPLETED ·Phase: NA
-
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
NCT00579124 ·Status: COMPLETED ·Phase: PHASE2
-
iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant
NCT02378012 ·Status: TERMINATED ·Phase: NA
-
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
NCT04746209 ·Status: RECRUITING ·Phase: PHASE2
-
70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014
NCT02441075 ·Status: COMPLETED ·Phase: NA
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
NCT03922724 ·Status: RECRUITING ·Phase: PHASE2
-
Randomized Double Cord Blood Transplant Study
NCT00067002 ·Status: COMPLETED ·Phase: PHASE2
-
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
NCT03459170 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
NCT01200017 ·Status: NO_LONGER_AVAILABLE
-
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
NCT00003187 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06839456 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
NCT00186628 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152139 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
NCT03145545 ·Status: AVAILABLE